Howard A. 'Skip' Burris III, MD Joins Elephas Biosciences Board for Growth in Immunotherapy Innovation

Elephas Biosciences Welcomes Dr. Howard A. 'Skip' Burris III to Its Board

In a significant move to bolster its leadership, Elephas Biosciences Corporation announced that Dr. Howard A. 'Skip' Burris III, MD, has joined its Board of Directors. This appointment is seen as a game-changer for the company, which is pioneering an innovative live tissue platform aimed at predicting immunotherapy responses. Dr. Burris brings a wealth of experience and a proven track record in oncology, making him a vital addition as Elephas gears up for the next phase of its commercial growth.

A Leader in Cancer Care

Dr. Burris is not just any addition to the board; he is a recognized leader in clinical research and drug development. He has previously served as the President and Chief Medical Officer of the Sarah Cannon Research Institute and was the former President of the American Society of Clinical Oncology (ASCO). His commitment to enhancing the landscape of cancer therapeutics is well documented, and he has been instrumental in advancing early-phase drug development from academic settings into community oncology practices. This has been pivotal in making cutting-edge treatments more accessible to patients.

Recognized as a 'Giant of Cancer Care in Drug Development' by OncLive in 2014, Dr. Burris has devoted his career to ensuring that patients have access to the latest and most effective therapies. His addition to Elephas will provide strategic insight as the company commercializes its elive™ platform, which assesses how live tumor samples react to immunotherapies.

The Mission of Elephas Biosciences

Cancer remains a leading cause of mortality worldwide, with the number of patients diagnosed projected to triple by 2060. Despite advancements in immunotherapy options, only 20% of patients currently see a response to these treatments. Elephas is on a mission to increase this statistic by enhancing predictive capabilities within immunotherapy treatments.

"For too long, immunotherapies have been administered without a reliable means of predicting patient responses. We are innovating that process by analyzing the behavior of living tumors, which will give clinicians and researchers critical insights for making informed treatment decisions," stated Dr. Burris. This approach promises a shift towards more personalized and effective cancer treatments.

Strategic Growth Ahead

Maneesh Arora, the founder and CEO of Elephas, expressed his enthusiasm about Dr. Burris’s involvement: "Dr. Burris has dedicated his career to transforming how cancer therapies reach patients. His vision closely aligns with our objective to provide real-time insights into immunotherapy responses, making his guidance crucial as we head into commercialization."

The elive platform developed by Elephas is built to provide a real-time characterization of immune responses by utilizing live biopsies while preserving the tumor’s native microenvironment. This is significant in addressing the heterogeneity found in tumors, which often complicates treatment decisions. By employing innovative methods to gather and analyze this data, Elephas aims to greatly improve patient outcomes in the face of oncological challenges.

As Elephas prepares to bring its groundbreaking platform to market, the expertise and leadership of Dr. Burris could be the key to revolutionizing treatment paradigms in cancer care. With a focus on developing effective immune response predictors, Elephas is poised to make a substantial impact in the world of oncology.

To learn more about Elephas Biosciences and their innovative work in immunotherapy response prediction, visit their official website at elephas.com and follow their journey on LinkedIn.